TY - JOUR AU - Staines, Henry AU - Kirwan, Daniela AU - Clark, David AU - Adams, Emily AU - Augustin, Yolanda AU - Byrne, Rachel AU - Cocozza, Michael AU - Cubas-Atienzar, Ana AU - Cuevas, Luis AU - Cusinato, Martina AU - Davies, Benedict M.O. AU - Davis, Mark AU - Davis, Paul AU - Duvoix, Annelyse AU - Eckersley, Nicholas AU - Forton, Daniel AU - Fraser, Alice AU - Garrod, Gala AU - Hadcocks, Linda AU - Hu, Qinxue AU - Johnson, Michael AU - Kay, Grant AU - Klekotko, Kesja AU - Lewis, Zawditu AU - Macallan, Derek AU - Mensah-Kane, Josephine AU - Menzies, Stefanie AU - Monahan, Irene AU - Moore, Catherine AU - Nebe-von-Caron, Gerhard AU - Owen, Sophie AU - Sainter, Chris AU - Sall, Amadou AU - Schouten, James AU - Williams, Christopher AU - Wilkins, John AU - Woolston, Kevin AU - Fitchett, Joseph R.A. AU - Krishna, Sanjeev AU - Planche, Tim T1 - IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection T2 - Emerging Infectious Disease journal PY - 2021 VL - 27 IS - 1 SP - 85 SN - 1080-6059 AB - We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29–May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%–8.5% of persons did not seroconvert 3–6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection. KW - SARS-CoV-2 KW - COVID-19 KW - diagnostics KW - immunology KW - antibody responses KW - respiratory infections KW - severe acute respiratory syndrome coronavirus 2 KW - 2019 novel coronavirus disease KW - coronavirus disease KW - zoonoses KW - viruses KW - coronavirus KW - antibodies KW - serology KW - United Kingdom DO - 10.3201/eid2701.203074 UR - https://wwwnc.cdc.gov/eid/article/27/1/20-3074_article ER - End of Reference